UK pharma group acquires Belgium’s EsoBiotec as it announces EU has approved Imfinzi lung cancer drug
Business live – latest updates
AstraZeneca has struck a $1bn (£773m) deal to buy a Belgian biotech company that specialises in cancer immunotherapies, the latest in a string of acquisitions that also yielded positive results for a late-stage rare disease drug on Monday.
EsoBiotec, a small privately held firm founded four years ago in Mont-Saint-Guibert, develops in-vivo cell therapies that empower the immune system to attack cancers, and could offer many more patients access to cell therapy treatments provided in minutes rather than weeks.
About Author
More Stories
Porsche reports steep fall in orders from Europe and China
‘Fruit of the devil’: Hainan’s betel nut sellers suffer from stuttering economy
Trump confirms 104% tariffs on Chinese goods as part of unfolding global trade war